Pub Date : 2025-11-01Epub Date: 2025-03-17DOI: 10.1016/j.recesp.2025.02.001
Danielle Medina-Hernández , Carlos Galán-Arriola , Javier Sánchez-González , Julien Ochala , Borja Ibáñez
{"title":"La cardiotoxicidad de las antraciclinas se asocia a alteraciones en la energética de la miosina cardiaca","authors":"Danielle Medina-Hernández , Carlos Galán-Arriola , Javier Sánchez-González , Julien Ochala , Borja Ibáñez","doi":"10.1016/j.recesp.2025.02.001","DOIUrl":"10.1016/j.recesp.2025.02.001","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 1012-1014"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-03-21DOI: 10.1016/j.recesp.2025.01.024
Chi-Hion Pedro Li , Lluís Asmarats , Albert Massó van Roessel , Helena Capellades , Estefanía Fernández-Peregrina , Dabit Arzamendi
{"title":"Diferencias según el sexo en la anatomía de la insuficiencia mitral y resultados de la reparación percutánea de borde a borde","authors":"Chi-Hion Pedro Li , Lluís Asmarats , Albert Massó van Roessel , Helena Capellades , Estefanía Fernández-Peregrina , Dabit Arzamendi","doi":"10.1016/j.recesp.2025.01.024","DOIUrl":"10.1016/j.recesp.2025.01.024","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 1010-1012"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-10DOI: 10.1016/j.recesp.2025.07.003
Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid-Álvarez , en representación de la ACI-SEC
Introduction and objectives
This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods
All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
Results
A total of 118 hospitals participated, with a marked increase in the number of catheterization laboratories. The number of diagnostic procedures rose by 3.6%. Percutaneous coronary interventions (PCI) also increased. Although PCI volumes grew compared with 2023, the trend toward a reduction in the number of stents used was confirmed, with greater use of drug-coated balloons both as standalone treatment and in hybrid strategies (14.3% of PCIs involved drug-coated balloons). Overall, the use of intracoronary diagnostic techniques increased, with 10.6% of PCIs guided by intracoronary imaging. Plaque modification techniques also continued to grow. Primary PCI increased slightly and remained the predominant treatment for myocardial infarction (98%). Structural interventions continued to expand, with substantial growth in transcatheter aortic valve implantation, percutaneous edge-to-edge mitral repair, tricuspid interventions, and left atrial appendage closure. Interventional treatment for acute pulmonary embolism increased again in 2024, especially with dedicated devices.
Conclusions
The 2024 Spanish cardiac catheterization and interventional cardiology registry showed overall growth in all procedures, both coronary and structural.
{"title":"Registro español de hemodinámica y cardiología intervencionista. XXXIV informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2024)","authors":"Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid-Álvarez , en representación de la ACI-SEC","doi":"10.1016/j.recesp.2025.07.003","DOIUrl":"10.1016/j.recesp.2025.07.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).</div></div><div><h3>Methods</h3><div>All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board<em>.</em></div></div><div><h3>Results</h3><div>A total of 118 hospitals participated, with a marked increase in the number of catheterization laboratories. The number of diagnostic procedures rose by 3.6%. Percutaneous coronary interventions (PCI) also increased. Although PCI volumes grew compared with 2023, the trend toward a reduction in the number of stents used was confirmed, with greater use of drug-coated balloons both as standalone treatment and in hybrid strategies (14.3% of PCIs involved drug-coated balloons). Overall, the use of intracoronary diagnostic techniques increased, with 10.6% of PCIs guided by intracoronary imaging. Plaque modification techniques also continued to grow. Primary PCI increased slightly and remained the predominant treatment for myocardial infarction (98%). Structural interventions continued to expand, with substantial growth in transcatheter aortic valve implantation, percutaneous edge-to-edge mitral repair, tricuspid interventions, and left atrial appendage closure. Interventional treatment for acute pulmonary embolism increased again in 2024, especially with dedicated devices.</div></div><div><h3>Conclusions</h3><div>The 2024 Spanish cardiac catheterization and interventional cardiology registry showed overall growth in all procedures, both coronary and structural.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 992-1003"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-03-28DOI: 10.1016/j.recesp.2025.02.005
Luigi P. Badano , Marco Penso , Michele Tomaselli , Kyu Kim , Alexandra Clement , Noela Radu , Geu-Ru Hong , Diana R. Hădăreanu , Alexandra Buta , Caterina Delcea , Samantha Fisicaro , Gianfranco Parati , Chi Young Shim , Denisa Muraru
Introduction and objectives
Significant secondary tricuspid regurgitation (STR) is associated with poor prognosis, but its heterogeneity makes predicting patient outcomes challenging. Our objective was to identify STR prognostic phenogroups.
Methods
We analyzed 758 patients with moderate-to-severe STR: 558 (74 ± 14 years, 55% women) in the derivation cohort and 200 (73 ± 12 years, 60% women) in the external validation cohort. The primary endpoint was a composite of heart failure hospitalization and all-cause mortality.
Results
We identified 3 phenogroups. The low-risk phenogroup (2-year event-free survival 80%, 95%CI, 74%-87%) had moderate STR, preserved right ventricular (RV) size and function, and a moderately dilated but normally functioning right atrium. The intermediate-risk phenogroup (HR, 2.20; 95%CI, 1.44-3.37; P < .001) included older patients with severe STR, and a mildly dilated but uncoupled RV. The high-risk phenogroup (HR, 4.67; 95%CI, 3.20-6.82; P < .001) included younger patients with massive-to-torrential tricuspid regurgitation, as well as severely dilated and dysfunctional RV and right atrium. Multivariable analysis confirmed the clustering as independently associated with the composite endpoint (HR, 1.40; 95%CI, 1.13-1.70; P = .002). A supervised machine learning model, developed to assist clinicians in assigning patients to the 3 phenogroups, demonstrated excellent performance both in the derivation cohort (accuracy = 0.91, precision = 0.91, recall = 0.91, and F1 score = 0.91) and in the validation cohort (accuracy = 0.80, precision = 0.78, recall = 0.78, and F1 score = 0.77).
Conclusions
The unsupervised cluster analysis identified 3 risk phenogroups, which could assist clinicians in developing more personalized treatment and follow-up strategies for STR patients.
重要的继发性三尖瓣反流（STR）与不良预后相关，但其异质性使得预测患者预后具有挑战性。我们的目的是确定STR预后表型。方法对758例中重度STR患者进行分析：衍生队列558例（74±14岁，55%为女性），外部验证队列200例（73±12岁，60%为女性）。主要终点是心力衰竭住院和全因死亡率的综合。结果共鉴定出3个表型组。低风险表型组（2年无事件生存率80%，95%CI, 74%-87%）有中度STR，保留右心室（RV）大小和功能，中度扩张但功能正常的右心房。中危表型组（HR, 2.20; 95%CI, 1.44-3.37; P < .001）包括严重STR的老年患者和轻度扩张但未耦合的RV。高危表型组（HR, 4.67; 95%CI, 3.20-6.82; P < .001）包括年轻的三尖瓣大量到剧烈反流的患者，以及严重扩张和功能不全的右心室和右心房。多变量分析证实聚类与复合终点独立相关（HR, 1.40; 95%CI, 1.13-1.70; P = 0.002）。为了帮助临床医生将患者分配到3个表型组，开发了一个监督机器学习模型，该模型在衍生队列（准确性= 0.91，精度= 0.91，召回率= 0.91，F1评分= 0.91）和验证队列（准确性= 0.80，精度= 0.78，召回率= 0.78，F1评分= 0.77）中都表现出色。结论无监督聚类分析确定了3个风险表型，有助于临床医生为STR患者制定更个性化的治疗和随访策略。
{"title":"Ecocardiografía avanzada y análisis de conglomerados para identificar fenogrupos de insuficiencia tricuspídea secundaria con diferente riesgo","authors":"Luigi P. Badano , Marco Penso , Michele Tomaselli , Kyu Kim , Alexandra Clement , Noela Radu , Geu-Ru Hong , Diana R. Hădăreanu , Alexandra Buta , Caterina Delcea , Samantha Fisicaro , Gianfranco Parati , Chi Young Shim , Denisa Muraru","doi":"10.1016/j.recesp.2025.02.005","DOIUrl":"10.1016/j.recesp.2025.02.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Significant secondary tricuspid regurgitation (STR) is associated with poor prognosis, but its heterogeneity makes predicting patient outcomes challenging. Our objective was to identify STR prognostic phenogroups.</div></div><div><h3>Methods</h3><div>We analyzed 758 patients with moderate-to-severe STR: 558 (74<!--> <!-->±<!--> <!-->14 years, 55% women) in the derivation cohort and 200 (73<!--> <!-->±<!--> <!-->12 years, 60% women) in the external validation cohort. The primary endpoint was a composite of heart failure hospitalization and all-cause mortality.</div></div><div><h3>Results</h3><div>We identified 3 phenogroups. The low-risk phenogroup (2-year event-free survival 80%, 95%<span>C</span>I, 74%-87%) had moderate STR, preserved right ventricular (RV) size and function, and a moderately dilated but normally functioning right atrium. The intermediate-risk phenogroup (HR, 2.20; 95%CI, 1.44-3.37; <em>P</em> <!--><<!--> <!-->.001) included older patients with severe STR, and a mildly dilated but uncoupled RV. The high-risk phenogroup (HR, 4.67; 95%CI, 3.20-6.82; <em>P</em> <!--><<!--> <!-->.001) included younger patients with massive-to-torrential tricuspid regurgitation, as well as severely dilated and dysfunctional RV and right atrium. Multivariable analysis confirmed the clustering as independently associated with the composite endpoint (HR, 1.40; 95%CI, 1.13-1.70; <em>P</em> <!-->=<!--> <!-->.002). A supervised machine learning model, developed to assist clinicians in assigning patients to the 3 phenogroups, demonstrated excellent performance both in the derivation cohort (accuracy<!--> <!-->=<!--> <!-->0.91, precision<!--> <!-->=<!--> <!-->0.91, recall<!--> <!-->=<!--> <!-->0.91, and F1 score<!--> <!-->=<!--> <!-->0.91) and in the validation cohort (accuracy<!--> <!-->=<!--> <!-->0.80, precision<!--> <!-->=<!--> <!-->0.78, recall<!--> <!-->=<!--> <!-->0.78, and F1 score<!--> <!-->=<!--> <!-->0.77).</div></div><div><h3>Conclusions</h3><div>The unsupervised cluster analysis identified 3 risk phenogroups, which could assist clinicians in developing more personalized treatment and follow-up strategies for STR patients.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 838-847"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-03-21DOI: 10.1016/j.recesp.2025.01.017
Jesús Peteiro , Marina Combarro , Gonzalo Barge-Caballero , Alberto Bouzas-Mosquera , José Larrañaga-Moreira , José M. Vázquez-Rodríguez
{"title":"Preservación apical en el ecocardiograma de esfuerzo por sospecha de amiloidosis cardiaca","authors":"Jesús Peteiro , Marina Combarro , Gonzalo Barge-Caballero , Alberto Bouzas-Mosquera , José Larrañaga-Moreira , José M. Vázquez-Rodríguez","doi":"10.1016/j.recesp.2025.01.017","DOIUrl":"10.1016/j.recesp.2025.01.017","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 918-922"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-03-15DOI: 10.1016/j.recesp.2025.02.019
Òscar Miró , Olivier Peyrony , Joan Carles Trullàs , Aitor Alquézar-Arbé , Julio Núñez , Pedro López-Ayala , Javier Jacob , Héctor Bueno , Manuel Montero-Pérez-Barquero , José Carlos Arévalo-Lorido , Rafael de la Espriella , Gema Miñana , Juan Sanchis , Pere Llorens
Introduction and objectives
To identify phenotypes in heart failure with preserved ejection fraction (HFpEF), compare mortality, and investigate whether treatments have different effects according to phenotype.
Methods
We performed a secondary analysis of 8161 patients with HFpEF included in Spanish cardiology (INCLIVA), internal medicine (RICA), and emergency (EAHFE) registries. Phenotypic clusters based on 16 baseline characteristics were identified using latent class analysis. We analyzed crude and treatment-adjusted 1-year survival, the associations between each treatment and mortality, and their interactions with phenotype.
Results
We identified 4 distinct clusters. One-year mortality was 18.7%. Cluster 4 (younger women with a valvular heart disease phenotype) had the lowest mortality (13.7%; reference category), which increased progressively in cluster 2 (cardiometabolic phenotype; mortality: 15.7%; adjusted HR, 1.28; 95%CI, 1.06-1.54), cluster 3 (very elderly female phenotype; mortality: 20.4%; adjusted HR, 1.63; 95%CI, 1.40-1.90), and cluster 1 (male cardiorespiratory phenotype; mortality: 24.0%; adjusted HR, 1.81; 95%CI, 1.53-2.13). The results were very similar when each registry was analyzed individually. Treatment with renin-angiotensin system inhibitors was associated with better survival in all clusters, beta-blockers were beneficial in cluster 1, and anticoagulants in cluster 4. However, none of the treatments showed a differential association with prognosis according to phenotype.
Conclusions
This study defines 4 HFpEF phenotypes with significantly different prognoses. Among the treatments analyzed, only renin-angiotensin system inhibitors seemed to have a generalized survival benefit, and none demonstrated a differential effect based on phenotype.
{"title":"Identificación de fenotipos en la insuficiencia cardiaca con fracción de eyección conservada a partir de 8.161 pacientes de 3 cohortes españolas","authors":"Òscar Miró , Olivier Peyrony , Joan Carles Trullàs , Aitor Alquézar-Arbé , Julio Núñez , Pedro López-Ayala , Javier Jacob , Héctor Bueno , Manuel Montero-Pérez-Barquero , José Carlos Arévalo-Lorido , Rafael de la Espriella , Gema Miñana , Juan Sanchis , Pere Llorens","doi":"10.1016/j.recesp.2025.02.019","DOIUrl":"10.1016/j.recesp.2025.02.019","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>To identify phenotypes in heart failure with preserved ejection fraction (HFpEF), compare mortality, and investigate whether treatments have different effects according to phenotype.</div></div><div><h3>Methods</h3><div>We performed a secondary analysis of 8161 patients with HFpEF included in Spanish cardiology (INCLIVA), internal medicine (RICA), and emergency (EAHFE) registries. Phenotypic clusters based on 16 baseline characteristics were identified using latent class analysis. We analyzed crude and treatment-adjusted 1-year survival, the associations between each treatment and mortality, and their interactions with phenotype.</div></div><div><h3>Results</h3><div>We identified 4 distinct clusters. One-year mortality was 18.7%. Cluster 4 (younger women with a valvular heart disease phenotype) had the lowest mortality (13.7%; reference category), which increased progressively in cluster 2 (cardiometabolic phenotype; mortality: 15.7%; adjusted HR, 1.28; 95%<span>C</span>I, 1.06-1.54), cluster 3 (very elderly female phenotype; mortality: 20.4%; adjusted HR, 1.63; 95%CI, 1.40-1.90), and cluster 1 (male cardiorespiratory phenotype; mortality: 24.0%; adjusted HR, 1.81; 95%CI, 1.53-2.13). The results were very similar when each registry was analyzed individually. Treatment with renin-angiotensin system inhibitors was associated with better survival in all clusters, beta-blockers were beneficial in cluster 1, and anticoagulants in cluster 4. However, none of the treatments showed a differential association with prognosis according to phenotype.</div></div><div><h3>Conclusions</h3><div>This study defines 4 HFpEF phenotypes with significantly different prognoses. Among the treatments analyzed, only renin-angiotensin system inhibitors seemed to have a generalized survival benefit, and none demonstrated a differential effect based on phenotype.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 896-905"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-05-05DOI: 10.1016/j.recesp.2025.04.010
Francisco González-Vílchez , Luis Almenar-Bonet , Manuel Gómez-Bueno , María G. Crespo-Leiro , Manuel Cobo-Belaustegui , Manuel Crespín-Crespín , Carlos Ortiz-Bautista , Juan F. Delgado-Jiménez , Marta de Antonio-Ferrer , José Manuel Sobrino-Márquez , en representación de los Equipos Españoles de Trasplante Cardiaco , Miguel Llano-Cardenal , José Antonio Vázquez de Prada , Francisco Nistal-Herrera , Cristina Castrillo , Beatriz Díaz-Molina , Vanesa Alonso-Fernández , Cristina Fidalgo-Muñiz , Diego Rangel-Sousa , Antonio Grande-Trillo , Ferrán Gran-Ipiña
Introduction and objectives
This report presents updated data on heart transplants in Spain, including procedures carried out in 2024. It reviews trends over the past decade (2015-2024) in donor and recipient characteristics, surgical techniques, immunosuppression strategies, and survival rates.
Methods
Data were drawn from the Spanish heart transplant registry, which is updated annually. The analysis includes 347 transplants performed in 2024, as well as procedures from 2015 to 2023 (n = 2721).
Results
In 2024, the number of heart transplants increased by 6.8% compared with 2023. There were no significant changes in recipient age or sex, but the proportion of urgent transplants rose to 47.0%. Use of circulatory support devices increased, particularly extracorporeal membrane oxygenation. The average donor age showed a slight increase in 2024, although the long-term trend remained downward. Donation after circulatory death accounted for 29.1% of transplants in 2024. One-year survival rates improved, reaching 85.2% for transplants performed between 2021 and 2023.
Conclusions
The number of heart transplants continued to grow, nearing historic highs, largely due to the expansion of donation after circulatory death. Improved 1-year survival reflects the maturity of transplant programs, advances in surgical and medical management, and better pretransplant conditions in recipients.
{"title":"Registro español de trasplante cardiaco. XXXVI informe oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología","authors":"Francisco González-Vílchez , Luis Almenar-Bonet , Manuel Gómez-Bueno , María G. Crespo-Leiro , Manuel Cobo-Belaustegui , Manuel Crespín-Crespín , Carlos Ortiz-Bautista , Juan F. Delgado-Jiménez , Marta de Antonio-Ferrer , José Manuel Sobrino-Márquez , en representación de los Equipos Españoles de Trasplante Cardiaco , Miguel Llano-Cardenal , José Antonio Vázquez de Prada , Francisco Nistal-Herrera , Cristina Castrillo , Beatriz Díaz-Molina , Vanesa Alonso-Fernández , Cristina Fidalgo-Muñiz , Diego Rangel-Sousa , Antonio Grande-Trillo , Ferrán Gran-Ipiña","doi":"10.1016/j.recesp.2025.04.010","DOIUrl":"10.1016/j.recesp.2025.04.010","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This report presents updated data on heart transplants in Spain, including procedures carried out in 2024. It reviews trends over the past decade (2015-2024) in donor and recipient characteristics, surgical techniques, immunosuppression strategies, and survival rates.</div></div><div><h3>Methods</h3><div>Data were drawn from the Spanish heart transplant registry, which is updated annually. The analysis includes 347 transplants performed in 2024, as well as procedures from 2015 to 2023 (n<!--> <!-->=<!--> <!-->2721).</div></div><div><h3>Results</h3><div>In 2024, the number of heart transplants increased by 6.8% compared with 2023. There were no significant changes in recipient age or sex, but the proportion of urgent transplants rose to 47.0%. Use of circulatory support devices increased, particularly extracorporeal membrane oxygenation. The average donor age showed a slight increase in 2024, although the long-term trend remained downward. Donation after circulatory death accounted for 29.1% of transplants in 2024. One-year survival rates improved, reaching 85.2% for transplants performed between 2021 and 2023.</div></div><div><h3>Conclusions</h3><div>The number of heart transplants continued to grow, nearing historic highs, largely due to the expansion of donation after circulatory death. Improved 1-year survival reflects the maturity of transplant programs, advances in surgical and medical management, and better pretransplant conditions in recipients.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 906-915"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-02-13DOI: 10.1016/j.recesp.2025.02.007
Víctor Manuel López-Espinosa, Isabel Navarro-Pelayo Torres, Juan Emilio Alcalá-López
{"title":"Rabdomiosarcoma pleomórfico arterial pulmonar con invasión a mediastino","authors":"Víctor Manuel López-Espinosa, Isabel Navarro-Pelayo Torres, Juan Emilio Alcalá-López","doi":"10.1016/j.recesp.2025.02.007","DOIUrl":"10.1016/j.recesp.2025.02.007","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 927-928"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-07-24DOI: 10.1016/j.recesp.2025.06.007
Salvatore Brugaletta
{"title":"Impacto de la exclusión de accesos transapicales en los resultados por sexos del implante percutáneo de válvula aórtica: ¿una limitación metodológica? Respuesta","authors":"Salvatore Brugaletta","doi":"10.1016/j.recesp.2025.06.007","DOIUrl":"10.1016/j.recesp.2025.06.007","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Page 931"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号